Yunoki K et al. Atherosclerosis 2011 Epub Apr 22.
-
Upload
colin-gavin-shields -
Category
Documents
-
view
213 -
download
0
Transcript of Yunoki K et al. Atherosclerosis 2011 Epub Apr 22.
![Page 1: Yunoki K et al. Atherosclerosis 2011 Epub Apr 22.](https://reader033.fdocuments.net/reader033/viewer/2022051821/5697bfaa1a28abf838c9a297/html5/thumbnails/1.jpg)
Yunoki K et al. Atherosclerosis 2011 Epub Apr 22
![Page 2: Yunoki K et al. Atherosclerosis 2011 Epub Apr 22.](https://reader033.fdocuments.net/reader033/viewer/2022051821/5697bfaa1a28abf838c9a297/html5/thumbnails/2.jpg)
Baseline clinical characteristics
Yunoki K et al. Atherosclerosis 2011 Epub Apr 22
![Page 3: Yunoki K et al. Atherosclerosis 2011 Epub Apr 22.](https://reader033.fdocuments.net/reader033/viewer/2022051821/5697bfaa1a28abf838c9a297/html5/thumbnails/3.jpg)
Laboratory data and endothelial function during a fasting state before and after treatment for 4 weeks
in the ezetimibe and control groups
Yunoki K et al. Atherosclerosis 2011 Epub Apr 22
![Page 4: Yunoki K et al. Atherosclerosis 2011 Epub Apr 22.](https://reader033.fdocuments.net/reader033/viewer/2022051821/5697bfaa1a28abf838c9a297/html5/thumbnails/4.jpg)
(A–C) Postprandial changes in serum TG, RLP-C and apoB-48 levels and the AUC for postprandial serum TG, RLP-C and apoB-48 levels before and after treatment for 4 weeks in the ezetimibe and control groups (D) Postprandial changes in %FMD and changes in maximum reduction of %FMD after the cookie test (max Δ%FMD) before and after treatment for 4 weeks in the ezetimibe and control groups
Open bar indicates ezetimibe group; solid bar, control group Data are expressed as mean ± SE. *P < 0.05, vs. before treatment
Yunoki K et al. Atherosclerosis 2011 Epub Apr 22
![Page 5: Yunoki K et al. Atherosclerosis 2011 Epub Apr 22.](https://reader033.fdocuments.net/reader033/viewer/2022051821/5697bfaa1a28abf838c9a297/html5/thumbnails/5.jpg)
Yunoki K et al. Atherosclerosis 2011 Epub Apr 22
Postprandial changes in serum TG levels and the AUC for postprandial serum TG levels before and after treatment
for 4 weeks in the ezetimibe and control groups
(open bar indicates ezetimibe group; solid bar, control group)Data are expressed as mean ± SE. *P < 0.05, vs. before treatment
![Page 6: Yunoki K et al. Atherosclerosis 2011 Epub Apr 22.](https://reader033.fdocuments.net/reader033/viewer/2022051821/5697bfaa1a28abf838c9a297/html5/thumbnails/6.jpg)
Yunoki K et al. Atherosclerosis 2011 Epub Apr 22
Postprandial changes in serum RLP-C levels and the AUC for postprandial serum RLP-C levels before and after
treatment for 4 weeks in the ezetimibe and control groups
(open bar indicates ezetimibe group; solid bar, control group)Data are expressed as mean ± SE. *P < 0.05, vs. before treatment
![Page 7: Yunoki K et al. Atherosclerosis 2011 Epub Apr 22.](https://reader033.fdocuments.net/reader033/viewer/2022051821/5697bfaa1a28abf838c9a297/html5/thumbnails/7.jpg)
Yunoki K et al. Atherosclerosis 2011 Epub Apr 22
Postprandial changes in serum apoB-48 levels and the AUC for postprandial serum apoB-48 levels before and after
treatment for 4 weeks in the ezetimibe and control groups
(open bar indicates ezetimibe group; solid bar, control group)Data are expressed as mean ± SE. *P < 0.05, vs. before treatment
![Page 8: Yunoki K et al. Atherosclerosis 2011 Epub Apr 22.](https://reader033.fdocuments.net/reader033/viewer/2022051821/5697bfaa1a28abf838c9a297/html5/thumbnails/8.jpg)
Yunoki K et al. Atherosclerosis 2011 Epub Apr 22
Postprandial changes in %FMD and changes in maximum reduction of %FMD after the cookie test
(max Δ%FMD) before and after treatment for 4 weeks in the ezetimibe and control groups
Data are expressed as mean ± SE. *P < 0.05, vs. before treatment